Retreatment and maintenance therapy with infliximab in fistulizing Crohn' disease
| Autor: | V. Cadahía, A. García-Carbonero, L. Rodrigo, E. Gonzalez-Ballina, R. de Francisco, Dolores Fuentes, J. M. Pérez-Pariente, P. Niño, María de Lourdes Moreno, R. Tojo |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Adult
Male medicine.medical_specialty Time Factors Adolescent Crohn Disease Gastrointestinal Agents Maintenance therapy Intestinal Fistula medicine Humans Initial treatment Adverse effect Complete response Aged Crohn's disease business.industry Every Eight Weeks Gastroenterology Antibodies Monoclonal General Medicine Middle Aged medicine.disease Infliximab Surgery Repeated doses Retreatment Female Fistulizing Crohn' disease business Algorithms medicine.drug |
| Zdroj: | Revista Española de Enfermedades Digestivas v.96 n.8 2004 SciELO España. Revistas Científicas Españolas de Ciencias de la Salud instname |
| ISSN: | 1130-0108 |
| DOI: | 10.4321/s1130-01082004000800004 |
| Popis: | Objectives: infliximab has clearly demonstrated its efficacy in the short-term treatment of fistulizing Crohn' disease. We present here the results of retreatment and long-term maintenance therapy. Patients and methods: eighty one consecutive patients with active fistulizing Crohn' disease, in whom previous treatments had failed, were treated with infliximab. All patients received as the initial treatment of 5 mg/kg i.v. infusions (weeks 0, 2, and 6). Those patients who failed to respond after the initial cycle (group 1, n= 25), or those who relapsed after having responded (group 2, n=13), received retreatment with three similar doses (weeks 0,2, and 6). Those who responded to retreatment were included in a long-term maintenance programme (n=44), with repeated doses (5 mg/kg i.v. infusions) every eight weeks for 1-2 years. Results: in the initial treatment 56% of the patients responded partially; this response being complete in 44%. In the retreatment, 28% of group 1 (non-responders) presented a complete response, compared to 77% in group 2 (relapsers) (p< 0.0001). In the maintenance treatment, the global response was 88% (39/44). The mean number of doses per patient was 4.4 ± 2 (range 1-9) with a duration of 36 ± 12 weeks (range 8-72). Adverse effects were not significantly increased in either treatment. Conclusions: both retreatment and long-term maintenance therapy with infliximab, are highly effective and well tolerated in fistulizing Crohn' disease patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|